Comorbidities are associated with poorer outcomes in community patients with rheumatoid arthritis

Rheumatology (United Kingdom)

Volumn 52, Issue 10, 2013, Pages 1809-1817

  Ranganath, Veena K ^a   Maranian, Paul ^a   Elashoff, David A ^a   Woodworth, Thasia ^a   Khanna, Dinesh ^b   Hahn, Theodore ^c   Sarkisian, Catherine ^c   Kremer, Joel M ^d   Furst, Daniel E ^a   Paulus, Harold E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^d Center for Rheumatology LLP   (United States)

Author keywords

Age; Comorbidities; Remission; Rheumatoid arthritis

Indexed keywords

ANTIRHEUMATIC AGENT; AZATHIOPRINE; BIOLOGICAL PRODUCT; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DRUG THERAPY; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; MINOCYCLINE; PENICILLAMINE; PREDNISONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; AGE; AGED; ALCOHOLISM; ANEMIA; ARTICLE; CEREBROVASCULAR ACCIDENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL DISEASE ACTIVITY INDEX; COMMUNITY; COMORBIDITIES; COMORBIDITY; DEPRESSION; DISEASE ACTIVITY; DISEASE DURATION; DRUG THERAPY; DRY EYE; EPIDEMIOLOGY; FEMALE; FOLLOW UP; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL HEMORRHAGE; GROUPS BY AGE; HEALTH ASSESSMENT QUESTIONNAIRE; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MIDDLE AGED; MODIFIED HEALTH ASSESSMENT QUESTIONNAIRE; OSTEOARTHRITIS; OUTCOME ASSESSMENT; PARKINSON DISEASE; PRIORITY JOURNAL; REGISTER; REMISSION; RHEUMATOID ARTHRITIS; SEVERITY OF ILLNESS INDEX; SKIN CANCER; SPINE DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; UNITED STATES; VERY ELDERLY; XEROSTOMIA;

AGE; COMORBIDITIES; REMISSION; RHEUMATOID ARTHRITIS;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL AGENTS; COMORBIDITY; DRUG THERAPY; EPIDEMIOLOGY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; THERAPEUTIC USE; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84888793924     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ket224     Document Type: Article

References (47)

1. Smolen JS, Aletaha D, Bijlsma JW et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.
2. Doran MF, Crowson CS, Pond GR et al. Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002;46:2294-300.
3. Doran MF, Crowson CS, Pond GR et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002;46:2287-93.
4. Weyand CM, Goronzy JJ. Premature immunosenescence in rheumatoid arthritis. J Rheumatol 2002;29:1141-6.
5. Weyand CM, Fulbright JW, Goronzy JJ. Immunosenescence, autoimmunity, and rheumatoid arthritis. Exp Gerontol 2003;38:833-41.
6. Doran MF, Pond GR, Crowson CS et al. Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period. Arthritis Rheum 2002;46:625-31.
7. Rasch EK, Hirsch R, Paulose-Ram R et al. Prevalence of rheumatoid arthritis in persons 60 years of age and older in the United States: effect of different methods of case classification. Arthritis Rheum 2003;48:917-26.
8. Burmester GR, Ferraccioli G, Flipo RM et al. Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, openlabel, twelve-week study. Arthritis Rheum 2008;59:32-41.
9. Sokka T, Makinen H, Hannonen P et al. Most people over age 50 in the general population do not meet ACR remission criteria or OMERACT minimal disease activity criteria for rheumatoid arthritis. Rheumatology 2007;46:1020-3.
10. Sokka T, Hetland ML, Makinen H et al. Remission and rheumatoid arthritis: data on patients receiving usual care in twenty-four countries. Arthritis Rheum 2008;58:2642-51.
11. Treharne GJ, Douglas KM, Iwaszko J et al. Polypharmacy among people with rheumatoid arthritis: the role of age, disease duration and comorbidity. Musculoskeletal Care 2007;5:175-90.
12. WesthoffG, Weber C, Zink A. [Comorbidity in rheumatoid arthritis of early onset. Effects on outcome parameters]. Z Rheumatol 2006;65:487-4, 496.
13. Fleischmann R, Baumgartner SW, Weisman MH et al. Long term safety of etanercept in elderly subjects with rheumatic diseases. Ann Rheum Dis 2006;65:379-84.
14. Fleischmann R, Iqbal I. Risk: benefit profile of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis. Drugs Aging 2007;24:239-54.
15. Fleischmann RM, Baumgartner SW, Tindall EA et al. Response to etanercept (Enbrel) in elderly patients with rheumatoid arthritis: a retrospective analysis of clinical trial results. J Rheumatol 2003;30:691-6.
16. Fraenkel L, Rabidou N, Dhar R. Are rheumatologists' treatment decisions influenced by patients'age? Rheumatology 2006;45:1555-7.
17. Kievit W, van HL, van RP, Fraenkel L. Factors that influence rheumatologists'decisions to escalate care in rheumatoid arthritis: results from a choice-based conjoint analysis. Arthritis Care Res 2010;62:842-7.
18. Ogasawara M, Tamura N, Onuma S et al. Observational cross-sectional study revealing less aggressive treatment in Japanese elderly than nonelderly patients with rheumatoid arthritis. J Clin Rheumatol 2010;16:370-4.
19. Tutuncu Z, Reed G, Kremer J et al. Do patients with olderonset rheumatoid arthritis receive less aggressive treatment? Ann Rheum Dis 2006;65:1226-9.
20. Furst DE, Chang H, Greenberg JD et al. Prevalence of low hemoglobin levels and associations with other disease parameters in rheumatoid arthritis patients: evidence from the CORRONA registry. Clin Exp Rheumatol 2009;27:560-6.
21. Greenberg JD, Kremer JM, Curtis JR et al. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis 2011;70:576-82.
22. Greenberg JD, Reed G, Decktor D et al. A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. Ann Rheum Dis 2012;71:1134-42.
23. Ranganath VK, Paulus HE, Onofrei A et al. Functional improvement after patients with rheumatoid arthritis start a new disease modifying antirheumatic drug (DMARD) associated with frequent changes in DMARD: the CORRONA database. J Rheumatol 2008;35:1966-71.
24. Sokolove J, Strand V, Greenberg JD et al. Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. Ann Rheum Dis 2010;69:1612-7.
25. Pincus T, Summey JA, Soraci SA Jr et al. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum 1983;26:1346-53.
26. Bayliss EA, Ellis JL, Steiner JF. Subjective assessments of comorbidity correlate with quality of life health outcomes: initial validation of a comorbidity assessment instrument. Health Qual Life Outcomes 2005;3:51.
27. Margolis KL, Lihong Q, Brzyski R et al. Validity of diabetes self-reports in the Women's Health Initiative: comparison with medication inventories and fasting glucose measurements. Clin Trials 2008;5:240-7.
28. Mukerji SS, Duffy SA, Fowler KE et al. Comorbidities in head and neck cancer: agreement between self-report and chart review. Otolaryngol Head Neck Surg 2007;136:536-42.
29. Wada K, Yatsuya H, Ouyang P et al. Self-reported medical history was generally accurate among Japanese workplace population. J Clin Epidemiol 2009;62:306-13.
30. Aletaha D, Ward MM, Machold KP et al. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum 2005;52:2625-36.
31. Atzeni F, Cazzola M, Benucci M et al. Chronic widespread pain in the spectrum of rheumatological diseases. Best Pract Res Clin Rheumatol 2007;25:165-71.
32. Toms J, Soukup T, Bradna P et al. Disease activity composite indices in patients with rheumatoid arthritis and concomitant fibromyalgia. J Rheumatol 2010;37:468.
33. Krishnan E, Hakkinen A, Sokka T et al. Impact of age and comorbidities on the criteria for remission and response in rheumatoid arthritis. Ann Rheum Dis 2005;64:1350-2.
34. Michaud K, Wolfe F. Patterns of comorbidity in rheumatic disorders [abstract]. Arthritis Rheum 2007;54:S339.
35. Radner H, Smolen JS, Aletaha D. Impact of comorbidity on physical function in patients with rheumatoid arthritis. Ann Rheum Dis 2010;69:536-41.
36. Radner H, Smolen JS, Aletaha D. Comorbidity affects all domains of physical function and quality of life in patients with rheumatoid arthritis. Rheumatology 2011;50:381-8.
37. Verbrugge LM, Lepkowski JM, Imanaka Y. Comorbidity and its impact on disability. Milbank Q 1989;67:450-84.
38. Verbrugge LM, Lepkowski JM, Konkol LL. Levels of disability among U.S. adults with arthritis. J Gerontol 1991;46:S71-S83.
39. Michaud K, Wallenstein G, Wolfe F. Treatment and nontreatment predictors of health assessment questionnaire disability progression in rheumatoid arthritis: a longitudinal study of 18,485 patients. Arthritis Care Res 2011;63:366-72.
40. Charlson ME, Pompei P, Ales KL et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83.
41. Greenfield S, Apolone G, McNeil BJ et al. The importance of co-existent disease in the occurrence of postoperative complications and one-year recovery in patients undergoing total hip replacement. Comorbidity and outcomes after hip replacement. Med Care 1993;31:141-54.
42. Michaud K, Wolfe F. Comorbidities in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2007;21:885-906.
43. Von KM, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992;45:197-203.
44. Gabriel SE, Crowson CS, O'Fallon WM. A comparison of two comorbidity instruments in arthritis. J Clin Epidemiol 1999;52:1137-42.
45. Wolfe F, Michaud K, Li T et al. Chronic conditions and health problems in rheumatic diseases: comparisons with rheumatoid arthritis, noninflammatory rheumatic disorders, systemic lupus erythematosus, and fibromyalgia. J Rheumatol 2010;37:305-15.
46. Hudson M, Bernatsky S, Taillefer S et al. Patients with systemic autoimmune diseases could not distinguish comorbidities from their index disease. J Clin Epidemiol 2008;61:654-62.
47. Kremer JM, Greenberg J. Interpreting registry-derived drug studies: does societal context matter? Arthritis Rheum 2009;60:3155-7.